Bitcoin price today: hovers around $115k amid rate cut bets, but caution remains
Investing.com - H.C. Wainwright has reiterated its Buy rating and $25.00 price target on Engene Holdings Inc. (NASDAQ:ENGN), representing nearly 383% upside from the current price of $5.18, ahead of the company’s fourth-quarter 2025 interim data for its detalimogene treatment. According to InvestingPro data, analyst consensus remains strongly bullish with a 1.7 rating (1.0 being most bullish).
The research firm highlighted that investor focus remains too concentrated on direct comparisons of complete response rates between emerging non-muscle invasive bladder cancer (NMIBC) therapies rather than operational advantages.
H.C. Wainwright noted that detalimogene’s value proposition centers on ease of use, logistical simplicity, and integration into existing outpatient workflows - factors particularly important to private equity-owned urology practices that manage over 75% of NMIBC patients outside academic centers.
The firm emphasized that detalimogene does not need to match the efficacy benchmarks set by competitors like cretostimogene or TAR-200 to achieve commercial success, as long as its safety profile remains acceptable.
H.C. Wainwright maintained that these operational advantages remain "among the most overlooked and defensive attributes" in the upcoming NMIBC market, supporting its 12-month price target of $25 for Engene stock.
In other recent news, enGene Holdings Inc. has achieved a significant milestone by reaching its target enrollment of 100 patients for the pivotal cohort of its Phase 2 LEGEND trial. This trial focuses on evaluating detalimogene voraplasmid in patients with high-risk, non-muscle invasive bladder cancer. Additionally, the U.S. Food and Drug Administration has granted the company’s lead therapy, detalimogene voraplasmid, the Regenerative Medicine Advanced Therapy (RMAT) designation, enhancing its regulatory pathway for treating high-risk bladder cancer.
Financial analysts have maintained positive ratings on enGene’s stock. H.C. Wainwright reiterated a buy rating, highlighting the progress in the LEGEND trial, while JMP Securities maintained a Market Outperform rating, citing the anticipated release of updated clinical data in the second half of 2025. Furthermore, Raymond James kept its Outperform rating following enGene’s fiscal second-quarter 2025 results, which showed a net loss of $25.8 million and earnings per share of $(0.51), both better than their estimates. Operating expenses increased by only 2% quarter-over-quarter, indicating a stabilization after a previous spike. These developments reflect enGene’s ongoing efforts and progress in their clinical and financial endeavors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.